TARGET VALIDATION METHODS FOR NEMATODE CONTROL AGENTS

Information

  • Research Project
  • 6405055
  • ApplicationId
    6405055
  • Core Project Number
    R43AI050313
  • Full Project Number
    1R43AI050313-01
  • Serial Number
    50313
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2001 - 23 years ago
  • Project End Date
    2/28/2002 - 22 years ago
  • Program Officer Name
    GOTTLIEB, MICHAEL
  • Budget Start Date
    9/1/2001 - 23 years ago
  • Budget End Date
    2/28/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/15/2001 - 23 years ago
Organizations

TARGET VALIDATION METHODS FOR NEMATODE CONTROL AGENTS

DESCRIPTION (provided by applicant): Parasitic nematodes infect over one half of the world's population, causing significant morbidity and mortality. Currently available methods of control have only partially alleviated this problem. A long term objective of the company's research is the development of novel pharmaceutical or immunological controls for nematode parasites of humans and animals; the current market for nematode control in animals alone is estimated to be as much as $1.52 billion annually. The primary goal of the research outlined in this application is the identification of appropriate free-living, parasite-related nematode species to use as models for actual parasites. A second focus of this work is the development of higher throughput methods of inducing down-regulation of specific genes to identify genes required for nematode fertility or viability. Successful completion of work in this proposal will provide new tools for the identification and validation of targets for novel nematicides. Targets identified in model organisms can then be validated in parasitic nematodes using modifications of methods developed in this work. PROPOSED COMMERCIAL APPLICATION: The results of the SBIR phase I project will lay the groundwork for the identification and evaluation of targets for anthelmintic agent discovery, including antibodies, small peptides, and chemicals. These results will reduce the time required to bring environmentally safe but effective anti-nematode drugs to market.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99958
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:99958\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    DIVERGENCE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAINT LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    63132
  • Organization District
    UNITED STATES